Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch

Executive Summary

As the third to market, Merck & Co. Inc.'s recently launched Zepatier brought in a modest $50m in sales during the first quarter – but the drug has had an outsized impact on the hepatitis C field, with competitors Gilead Sciences Inc. and AbbVie Inc. both citing the new competition among the reasons for their declining HCV product sales during the first quarter.

Advertisement

Related Content

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
Merck Defends Its Offensive Strategy For Keytruda
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Merck Is Finding PD-L1 Testing Is Helping Keytruda
Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
Tackling Tough-To-Treat Patients As HCV Cure Rates Near 100%
EASL 2016: Looking For A Competitive Edge In Hepatitis C

Topics

Advertisement
UsernamePublicRestriction

Register

SC065186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel